[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adebrelimab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adebrelimab":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,75,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100620135","phase-2-adebrelimab-plus-apatinib-combined-with-sox-regimen-as-conversion-therapy-for-gastric-cancer-100620135",false,"NCT07353684","Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer","Phase II Clinical Study of Adebrelimab Plus Apatinib and SOX Regimen for Conversion Therapy of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Age 18-75 years at the time of enrollment, with an estimated life expectancy of ≥ 3 months.\n* Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.\n* Unresectable locally advanced gastric or gastroesophageal junction adenocarcinoma (Stage III or IV), as determined by the investigator based on CT, MRI, and\u002For PET-CT.\n* Disease with conversion (translational) therapeutic potential, as assessed by the investigator.\n* No prior anti-tumor treatment, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other systemic anticancer therapies.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Adequate hematologic function within 14 days prior to enrollment:\n\n  * White blood cell count ≥ 3.5 × 10⁹\u002FL.\n  * Absolute neutrophil count ≥ 1.5 × 10⁹\u002FL.\n  * Hemoglobin ≥ 90 g\u002FL (9.0 g\u002FdL).\n  * Platelet count ≥ 100 × 10⁹\u002FL.\n  * Adequate hepatic function within 14 days prior to enrollment:Total bilirubin ≤ 1.5 × upper limit of normal (ULN);ALT and AST ≤ 2.5 × ULN in patients without liver metastases;ALT and AST ≤ 5 × ULN in patients with liver metastases;Adequate renal function:Serum creatinine ≤ 1.5 × ULN;Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for at least 12 weeks after the last dose.\n* Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose\n* Ability to understand and willingness to sign a written informed consent form\n* Expected to comply with study procedures and follow-up requirements\n\nExclusion Criteria:\n\n* HER2-positive gastric or gastroesophageal junction adenocarcinoma.\n* Conditions that may significantly affect oral drug absorption, including inability to swallow, persistent nausea or vomiting, chronic diarrhea, or intestinal obstruction.\n* Known hypersensitivity or allergy to adebrelimab, apatinib, oxaliplatin, S-1 (tegafur\u002Fgimeracil\u002Foteracil), or any of their excipients.\n* History of severe allergic reactions to monoclonal antibodies.\n* Active autoimmune disease or autoimmune disorders requiring systemic treatment.\n* Congenital or acquired immunodeficiency.\n* Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.\n* Administration of live attenuated vaccines within 4 weeks prior to the first dose or planned during the study period.\n* Severe infection within 4 weeks prior to initiation of study treatment.\n* History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Evidence of interstitial lung disease, including pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or severely impaired pulmonary function.\n* Uncontrolled hypertension despite at least 3 months of antihypertensive treatment.\n* Uncontrolled clinically significant cardiovascular disease.\n* High risk of severe bleeding, as judged by the investigator.\n* Peripheral neuropathy of Grade \\> 2 according to CTCAE.\n* Participation in another interventional clinical trial within 4 weeks prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.\n* Any condition that, in the investigator's judgment, makes the participant unsuitable for study participation.","ALL","18 Years","75 Years",{"count":20,"type":21},49,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This is a prospective, single-center, single-arm, open phase II clinical study. Forty-nine participants with pathologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer are scheduled to be enrolled in this study. All participants will be treated with 2 to 8 cycles of adebrelimab, apatinib, oxaliplatin, and tigio before surgery. Participants will evaluate the treatment effect after every 2 cycles of medication. By the investigator assessment as an operable subject, apatinib was discontinued for one cycle. The adjuvant treatment will be determined by the investigators based on the participants' postoperative pathology results. Participants requiring adjuvant therapy, with a postoperative interval of at least 4 weeks, but not more than 10 weeks. When the resection standard isn't met for 8 cycles of treatment, the treatment is switched to a maintenance phase, which the subject treatment regimen is determined by the investigator. During the treatment period, participants will receive the study drugs on Day 1 of each 21-day cycle until evidence of disease progression or unacceptable toxicity.",[27,28,29],"Adebrelimab","Adenocarcinoma of GE Junction","Adenocarcinoma of Stomach",[31,32,33,34],"adebrelimab","Adenocarcinoma of GE junction","Adenocarcinoma of stomach","conversion therapy","RECRUITING","2026-04-21",{"date":38,"type":39},"2026-04-22","ACTUAL",{"date":41,"type":39},"2025-05-11",{"date":43,"type":21},"2028-05-31",{"name":45,"class":46},"Beijing Friendship Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100598267","phase-2-a-study-on-the-first-line-treatment-of-small-cell-lung-cancer-with-adebrelimab-and-vunakizumab-and-chemotherapy-100598267","NCT07069270","A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy","A Prospective, Single-center, Single-arm Clinical Study of Adebrelimab in Combination With Vunakizumab and Chemotherapy as First-line Treatment for Extensious-stage Small Cell Lung Cancer","Inclusion Criteria:\n\n* 1\\. Age: 18 to 75 years old, both male and female are acceptable.\n* 2\\. Histologically or cytologically confirmed extensive-stage small cell Lung cancer (according to the Veterans Administration Lung Study Group, VALG staging);\n* 3\\. No previous systematic treatment;\n* 4\\. Life expectancy exceeds 3 months;\n* 5.ECOG physical condition score: 0 to 1 point;\n* 6\\. According to the RECIST 1.1 standard, the target lesion has at least one measurable diameter.\n* 7\\. Within one week before enrollment, the functions of important organs met the following criteria:\n\n  1. blood routine: white blood cell count (WBC) ≥ 3.0 × 109\u002FL; absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL; platelet (PLT) ≥ 100 × 109\u002FL; The hemoglobin content (HGB) is ≥ 9.0 g\u002FDl\n  2. Liver function: aspartate transferase (AST) ≤ 2.5 × ULN, alanine aminotransferase (ALT) ≤ 2.5 × ULN For subjects with liver metastases, their ALT and AST levels were ≤ 5 × ULN. Serum total bilirubin (TBIL) ≤ 1.5 × ULN (except for Gilbert syndrome ≤ 3 × ULN); albumin (ALB) ≥ 30.0 g\u002FL\n  3. Renal function: Serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl) ≥ 50 mL\u002Fminute (using the Cockcroft\u002FGault formula)\n  4. Coagulation function: The international normalized ratio (INR) is ≤ 1.5, and the activated partial thromboplastin time (APTT) is ≤ 1.5 × ULN\n  5. Others: Lipase ≤ 1.5 × ULN. If the lipase is greater than 1.5 × ULN and there is no clinical or radiological confirmation of pancreatitis, the patient can be enrolled. Amylase ≤ 1.5 × ULN. If the amylase is greater than 1.5 × ULN and there is no clinical or radiological confirmation of pancreatitis, the patient can be enrolled. alkaline phosphatase (ALP) ≤ 2.5 × ULN, for bone metastasis subjects, ALP ≤ 5 × ULN\n  6. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ 50%;\n* 8.Women of childbearing age must undergo a serum pregnancy study within 7 days before the first medication, and the result must be negative. Female subjects of childbearing age and male subjects whose partners are women of childbearing age must agree to contraception from the signing of the informed consent form until 24 weeks after the last administration of the study drug.\n* 9\\. The subjects voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.\n\nExclusion Criteria:\n\n* 1\\. There is a large amount of uncontrolled pleural effusion, pericardial effusion or ascites;\n* 2\\. The following heart disorders exist: (1) According to NYHA cardiac function classification, (1) Grade III-IV cardiac function; (2) Unstable angina pectoris or acute ischemia indicated by electrocardiogram or myocardial infarction occurred within one year; (3) Clinically significant supraventricular or ventricular arrhythmias and other conduction system abnormalities (including QTc interval ≥ 450ms in men and ≥470ms in women); (4) Clinically significant pericardial and myocardial diseases.\n* 3\\. Insufficient bone marrow reserve or organ function;\n* 4\\. Systemic immunomodulators (including but not limited to thymosin, interferon or interleukin-2) have been used for treatment within 4 weeks before enrollment;\n* 5\\. Corticosteroid hormones (\\> 10 mg\u002F day prednisone or equivalent dose) or other immunosuppressants were used within 2 weeks before enrollment;\n* 6\\. Have any active autoimmune diseases or a history of autoimmune diseases; Interstitial pneumonia, drug-induced pneumonia, radiation pneumonitis requiring steroid treatment, or active pneumonia with clinical symptoms;\n* 7\\. There was an active or uncontrolled severe infection (CTCAE 5.0 ≥ grade 2) within 2 weeks before enrollment, and\u002For received antibiotic treatment;\n* 8\\. Tuberculosis patients who are active or undergoing treatment;\n* 9\\. Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg), history of hypertensive crisis or hypertensive encephalopathy;\n* 10\\. Within 24 weeks before enrollment, there were hyperactive\u002Fvenous thrombotic events, such as cerebrovascular accidents (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.\n* 11\\. Has undergone invasive surgery within 4 weeks before enrollment;\n* 12\\. Positive for HBsAg and HBV DNA test value exceeding the upper limit of the normal reference value (1000 copies \u002FmL or 100 IU\u002FmL), or positive for HCV (HCV RNA or HCV Ab test indicating acute or chronic infection), or a history of HIV positivity;\n* 13\\. Patients who have received live vaccines within 12 weeks before enrollment;\n* 14\\. Known to be allergic to the research drug or excipients, and known to have a severe allergic reaction to any monoclonal antibody;\n* 15\\. A known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n* 16\\. Other malignant tumors concurrent within 5 years before enrollment are excluded, except for fully treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and ductal carcinoma in situ after radical resection.\n* 17\\. It is known that there are serious mental disorders, alcoholism, drug abuse or drug abuse, etc.\n* 18\\. Have received any other investigational drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the ICF;\n* 19\\. As determined by the researchers, the subjects have other factors that may lead to the forced termination of this study, such as non-compliance with the protocol, other serious diseases (including mental disorders) requiring concurrent treatment, severe laboratory test abnormalities, accompanied by family or social factors that may affect the safety of the subjects, or the collection of data and samples.",{"count":56,"type":21},28,[24],"This study is a prospective, single-center, single-arm clinical trial, with a planned enrollment of 28 cases.The first Adebrelimab +Vunakizumab +EC was administered within 72 hours after enrollment for 4 to 6 cycles.At the end of the combination phase, non-PD subjects entered the maintenance treatment period of Adebrelimab plus Vunakizumab.Treatment will continue until any of the following situations occur: disease progression in the subject, intolerable toxic and side effects, comorbidiments that affect further treatment, the investigator's decision to withdraw the subject from the study, or other reasons for non-compliance with the study treatment or the study procedures or protocols.",[60,27,61],"Vunakizumab","Small Cell Lung Cancer",[63,27,60],"Small cell lung cancer","NOT_YET_RECRUITING","2025-07-07",{"date":67,"type":39},"2025-07-16",{"date":69,"type":21},"2025-09-01",{"date":71,"type":21},"2028-01-01",{"name":73,"class":74},"Fujian Cancer Hospital","OTHER_GOV",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":47},"100595338","phase-2-a-single-arm-multicenter-prospective-clinical-study-of-adebrelimab-combined-with-apatinib-neoadjuvant-therapy-for-resectable-non-small-cell-lung-cancer-100595338","NCT07031154","A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer","Inclusion Criteria:\n\n* Participants must meet all of the following criteria to be enrolled in the study:\n* 18 years old ≤ age ≤70 years old, male or female;\n* ECOG PS score 0-1;\n* Patients who have not received systematic treatment before and agree to receive radical surgical treatment; Thoracic surgeons judge patients with no contraindications to surgery;\n* Stage II, IIIA, or selective stage IIIB (T3N2M0 only) squamous cell or non-squamous non-small cell lung cancer confirmed by histopathology or cytology and determined by the investigator to be capable of R0 resection for curative purposes. Staging should be based on the American Joint Committee on Cancer (AJCC)\u002FUnion International Against Cancer (UICC) NSCLC Staging System Version 8;\n\n  1. Not allowed to invade the heart, great blood vessels, trachea, recurrent laryngeal nerve, esophagus, vertebrae, protuberances,And T4 tumors with dispersed tumor nodules in different lung lobes on the same side;\n  2. Upper lung groove cancer is not allowed;N2 was defined as mediastinal lymph node non-giant metastases (lymph node diameter \\\u003C 2cm) confirmed by imaging or pathology and expected to be completely resectable.\n* There were enough tumor tissues to detect PD-L1 expression and PD-L1 ≥1%;\n* At least one measurable lesion (according to RECIST 1.1 criteria);\n* Expected survival of at least 12 weeks;\n* Other major organs (liver, kidney, blood system, etc.) function well:\n\n  1. Hemoglobin ≥90g\u002FL (no blood transfusion, no hematopoietic factors, and no drug correction within 2 weeks prior to the first dose);Absolute neutrophil count (ANC) ≥1.5×109\u002FL;\n  2. Platelet count ≥100×109\u002FL;\n  3. Total bilirubin ≤1.5 times the upper limit of normal value;\n  4. Alanine aminotransferase, ASpartate aminotransferase, alkaline phosphatase ≤2.5 times the upper limit of normal value;\n  5. Serum creatinine ≤1.5 times the upper limit of normal value; And endogenous creatinine clearance ≥60ml\u002Fmin;\n  6. International Standardized Ratio of prothrombin time (INR)≤1.5 and activated partial thromboplastin time (APTT)≤1.5 times the upper limit of normal for patients who have not received anticoagulant therapy.\n* No systemic metastasis (including M1a, M1b, M1c);\n* Complete excision is expected;\n* Lung function is good and can tolerate surgical treatment;\n* Fertile female subjects must have a negative pregnancy test (serum or urine) within 3 days prior to the start of the study drug, and be willing to use a medically approved highly effective contraceptive during the study period and 90 days after the last study drug administration(e.g. intrauterine devices, contraceptives, or condoms); Male subjects whose partner is a woman of reproductive age must consent to use effective contraception or have been surgically sterilized during the study period and 90 days after the last study dosing;\n* Subjects voluntarily participate in this clinical study and sign informed consent.\n\nExclusion Criteria:\n\n* Subjects will not be admitted to the study if they have any of the following conditions:\n* have received any anti-tumor therapy in the past, including radiotherapy, chemotherapy, immunotherapy and traditional Chinese medicine anti-tumor therapy (except the treatment of malignant tumors with radical treatment and no recurrence and metastasis for more than 5 years);\n* Subjects with non-squamous cell histological types of NSCLC with EGFR mutation positive or ALK positive. Non-squamous cell carcinoma subjects must undergo EGFR gene testing and ALK gene and\u002For immunohistochemical testing;\n* Patients with distant metastases (including M1a, M1b, and M1c);\n* Have any active autoimmune disease or history of autoimmune disease (such as uveitis, enteritis, hepatitis, pituitaritis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy), tuberculosis); Skin conditions (such as vitiligo, psoriasis, or alopecia) with complete remission of childhood asthma that do not require any intervention in adulthood and do not require systemic treatment may be included, but patients requiring medical intervention with bronchodilators may not be included;\n* Exclude evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, radiographic evidence of active pneumonia, and severe impairment of lung function;\n* Subjects who have received systemic treatment with corticosteroids (\\>10 mg\u002F day of prednisone or other equivalent hormones) or other immunosuppressants within 2 weeks prior to initial dosing. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses ≤10 mg\u002F day of prednisone efficacy;\n* Imaging (CT or MRI) shows that the tumor has invaded large blood vessels or the boundary with blood vessels is blurred; Or imaging (CT or MRI) showing the presence of any pulmonary cavities or necrotic lesions, as determined by the investigator;\n* Patients who had experienced arteriovenous thrombosis events, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism within 6 months before enrollment;\n* Had clinically significant bleeding symptoms or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, etc., or were receiving thrombolytic or anticoagulant therapy within 3 months before enrollment;\n* Obvious symptoms of hemoptysis or daily hemoptysis volume of 2.5mL or more within 1 month before enrollment;\n* Patients with hypertension who are not well controlled by antihypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); Or grade II or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥450ms in men and women)≥470ms); According to NYHA criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) \\\u003C 50% indicated by cardiac color ultrasound;\n* Major operations or serious external injuries of other systems were performed within 2 months before the start of the study;\n* Urine routine indicated urinary protein ≥(++), or 24h urinary protein ≥1g or severe hepatic and renal insufficiency;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Allergic to the experimental drug;\n* Co-existing with HIV infection or active viral hepatitis;\n* Pregnant or lactating women; The fertile subject is unwilling or unable to take effective contraceptive measures;\n* Those who suffer from neurological diseases or mental diseases and cannot cooperate;\n* Other malignancies developed within 5 or less years before admission, excluding adequately treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery;\n* Other situations deemed unsuitable for inclusion by the researcher.","70 Years",{"count":83,"type":21},43,[24],"To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.",[87,27,88],"Non-Small Cell Lung Cancer","Apatinib","2025-06-12",{"date":91,"type":39},"2025-06-22",{"date":93,"type":21},"2025-06-30",{"date":95,"type":21},"2027-02-01",{"name":97,"class":46},"The First Affiliated Hospital of Xiamen University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":47},"100513837","phase-2-single-arm-prospective-multicenter-clinical-study-of-tace-with-adebrelimab-and-bevacizumab-for-unresectable-hepatocellular-carcinoma-100513837","NCT05970666","Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age: 18 \\~ 75, both male and female；\n2. Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular carcinoma diagnosed by pathological histology or cytology examination, and at least one measurable lesions (according to the RECIST1.1 standard, the spiral CT scan of 10mm or short diameter of 15mm）；\n3. Patients without previous systematic treatment and inoperable resection \u002F radical ablation surgery, but who can tolerate TACE;\n4. The CNLC stage is Ⅱa-Ⅲb stage;\n5. The Child-Pugh grade of liver function is A grade or B grade (5-7 points);\n6. The ECOG PS score is 0-1 points;\n7. Expected survival period of 12 weeks;\n8. If the patient has active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be \\\u003C2000 IU \u002F mL (if the study site has only copy \u002F mL testing units, Must be \\\u003C12500 copy \u002F mL), And received at least 14 days before initiating anti-HBV treatment (according to local standard therapy, e. g. entecavir) and willing to receive antiviral treatment throughout the study; hepatitis C virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral treatment according to local standard treatment guidelines and liver function within grade CTCAE 1 elevation;\n9. Main organs function are normal and meet the following criteria: (1) The blood routine examination standards should be met with: (no blood transfusion within 14 days) A. Hemoglobin (HB), 90g \u002F L, B. White blood cell count (WBC) 3109 \u002F L C. Absolute neutrophil count (ANC) 1.5109 \u002F L, D. Platelet (PLT) 80109 \u002F L;(2) Biochemical examination shall meet the following standards: A. Bilirubin (BIL) \\\u003C1.5 times the upper limit of normal value (ULN); B. Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST \\\u003C5 ULN; C. Serum creatinine (Cr)≤1.5ULN；\n10. Women of childbearing age must have negative pregnancy test (serum) or urine HCG within 7 days before enrollment and are willing to use appropriate contraception during treatment and 24 weeks after the last administration of test drug; for men, surgical sterilization or agree to use appropriate contraception during and 24 weeks after the last administration of trial drug;\n11. The subjects volunteered to join the study and had good compliance with the follow-up.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma;\n3. Diffuse liver cancer;\n4. Patients with autoimmune diseases, organ \u002F hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ);\n5. Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness;\n6. Patients who have participated in other clinical trials in the recent three months;\n7. Previous history of other malignancies or have received targeted therapy and other PD-1 \u002F PD-L1 inhibitor therapy;\n8. Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment;\n9. Use of immunosuppressants or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose\\> 10mg \u002F day prednisone or other efficacy hormones);\n10. Liver function was graded as Child-Pugh C, which could not be improved by liver care treatment；\n11. esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment；\n12. Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. Platelet count \\\u003C50109 \u002F L and severe coagulation abnormalities against surgery (anticoagulation therapy and \u002F or anticoagulant therapy should be stopped for more than 1 week before radiation therapy);\n13. A stubborn amount of ascites, pleural fluid, malignant fluid;\n14. Active infection, especially the inflammation of the biliary tract system;\n15. Severe functional failure of the liver, kidney, heart, lung, brain and other major organs;\n16. Previously allergic to PD-1 \u002F PD-L1 mAb \u002F any component of the targeted drug or other similar trials;\n17. Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure\\> 140 mmHg, diastolic blood pressure\\> 90 mmHg);\n18. Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) \\\u003C50%;\n19. Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of\\> 1.0g);\n20. Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption;\n21. According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study;\n22. Patients with radiotherapy, targeted therapy, and other contraindications to immunotherapy.",{"count":105,"type":21},71,[24],"To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma",[27,109,110,111,112],"Hepatocellular Carcinoma","Transformation","Bevacizumab","TACE","2024-02-27",{"date":115,"type":39},"2024-02-28",{"date":117,"type":39},"2023-11-15",{"date":119,"type":21},"2026-11-15",{"name":97,"class":46}]